Key facts
- Lundbeck and Cradle have formed a partnership to develop treatments for brain disorders.
- The collaboration will initially focus on two antibody programs targeting CNS diseases.
- Cradle is an AI platform specializing in drug discovery and optimization.
H. Lundbeck A/S, a biopharmaceutical company dedicated to brain health, has announced a partnership with Cradle, a prominent AI platform. This collaboration aims to leverage AI for the discovery and optimization of treatments for brain disorders. The initial phase of the partnership will concentrate on advancing two antibody programs specifically designed to target central nervous system (CNS) diseases. The agreement signifies a strategic move by Lundbeck to integrate advanced AI capabilities into its research and development pipeline for neurological conditions.